P004 Neglected risk for of invasive candidiasis: s tudy of distribution, species differentiation and antifungal susceptibility pattern of Candidemia among patients with liver disease

IF 1.4 Q4 MYCOLOGY
Pradeep Kumar, Mohd Ayyub, P. Kale
{"title":"P004 Neglected risk for of invasive candidiasis: s tudy of distribution, species differentiation and antifungal susceptibility pattern of Candidemia among patients with liver disease","authors":"Pradeep Kumar, Mohd Ayyub, P. Kale","doi":"10.1093/mmy/myac072.P004","DOIUrl":null,"url":null,"abstract":"Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives Patients with liver disease (LD) are more predisposed to candidemia due to the dysfunctional Kupffer cells which fails to capture the circulating yeasts, thereby causing fungal dissemination. Candidemia is ten times more common among end-stage liver disease patients compared with other LD patients. Compared to those with abdominal candidiasis, ICU admission and mortality are found to be higher in liver transplant recipients (LTRs) with candidemia. Though a majority of Candida infection among LD patients are due to C. albicans, there has been an increasing prevalence of non-albicans isolates. This study was mainly aimed at species differentiation and antifungal susceptibility. Our objective was to study the pattern of Candida isolates from blood among patients with different LD states admitted to tertiary care Liver Hospital. To determine the distribution of Candidemia in patients with different liver disease states. To determine the various species of Candida isolated from blood in patients with liver diseases. To determine the anti-fungal susceptibility pattern of Candida isolates in blood in patients with liver disease. To determine the year-wise changing trends in Candida spp. isolated in blood and its anti-fungal susceptibility pattern in patients with liver disease. Materials and Methods This is a retrospective observational study conducted in the department of Microbiology at Institute of Liver and Biliary Sciences (ILBS), New Delhi. Ethical approval for this study (IEC/2021/84/NA06) was provided by the Institutional ethics committee/Institutional review board. A total of 118 LD patients with candidemia who were admitted to ILBS between January 2017 to December 2020 were included in the study. Clinical details of these patients were collected from the hospital information system. Patients with LD were divided into 4 groups—acute liver failure (ALF), acute on chronic liver failure (ACLF), chronic liver disease (CLD), and post-liver transplantation (Post-LT). Candida speciation as identified by VITEK® 2 (Biomérieux) and also its antifungal susceptibility pattern by broth microdilution. Results The mean age of the 118 LD patients was 48.6 ± 14.9 years [± standard deviation (SD)]. Among them 107 (90.7%) were males and 11 (9.3%) were females. Among the 118 LD patients, 6 (5.1%) were ALF patients, 32 (27.1%) were ACLF patients, 66 (55.9%) were CLD patients and 14 (11.9%) were post-LT patients. The most common Candida species isolated was C. tropicalis (22.9%), followed by C. glabrata (17.8%), C. albicans (16.9%), C. parapsilosis (12.7%), C. auris (8.5%), C. krusei (6.8%) and other Candida species (14.4%). The other Candida species isolated were C. haemulonii, C. kefyr, C. lusitaniae, C.pelliculosa, C. duobushaemulonii, C. lipolytica, and C. rugosa. The sensitivity to fluconazole (55.1%), voriconazole (86.4%), caspofungin (82.2%), micafungin (97.5%), flucytosine (80.5%), amphotericin B (86.4%). Mortality was 66%. Conclusion Our study shows that chronic liver disease, acute liver failure and liver transplantation are important risk factors for invasive candidiasis. There was a rise in the non-albicans Candida, especially C. tropicalis and C. glabrata. There is rising antifungal resistance to azoles and can lead to therapy failure. Hence antifungal sensitivity testing is essential in patients with these neglected risk factors to prevent mortality.","PeriodicalId":18325,"journal":{"name":"Medical mycology journal","volume":"1 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/mmy/myac072.P004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MYCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract Poster session 1, September 21, 2022, 12:30 PM - 1:30 PM Objectives Patients with liver disease (LD) are more predisposed to candidemia due to the dysfunctional Kupffer cells which fails to capture the circulating yeasts, thereby causing fungal dissemination. Candidemia is ten times more common among end-stage liver disease patients compared with other LD patients. Compared to those with abdominal candidiasis, ICU admission and mortality are found to be higher in liver transplant recipients (LTRs) with candidemia. Though a majority of Candida infection among LD patients are due to C. albicans, there has been an increasing prevalence of non-albicans isolates. This study was mainly aimed at species differentiation and antifungal susceptibility. Our objective was to study the pattern of Candida isolates from blood among patients with different LD states admitted to tertiary care Liver Hospital. To determine the distribution of Candidemia in patients with different liver disease states. To determine the various species of Candida isolated from blood in patients with liver diseases. To determine the anti-fungal susceptibility pattern of Candida isolates in blood in patients with liver disease. To determine the year-wise changing trends in Candida spp. isolated in blood and its anti-fungal susceptibility pattern in patients with liver disease. Materials and Methods This is a retrospective observational study conducted in the department of Microbiology at Institute of Liver and Biliary Sciences (ILBS), New Delhi. Ethical approval for this study (IEC/2021/84/NA06) was provided by the Institutional ethics committee/Institutional review board. A total of 118 LD patients with candidemia who were admitted to ILBS between January 2017 to December 2020 were included in the study. Clinical details of these patients were collected from the hospital information system. Patients with LD were divided into 4 groups—acute liver failure (ALF), acute on chronic liver failure (ACLF), chronic liver disease (CLD), and post-liver transplantation (Post-LT). Candida speciation as identified by VITEK® 2 (Biomérieux) and also its antifungal susceptibility pattern by broth microdilution. Results The mean age of the 118 LD patients was 48.6 ± 14.9 years [± standard deviation (SD)]. Among them 107 (90.7%) were males and 11 (9.3%) were females. Among the 118 LD patients, 6 (5.1%) were ALF patients, 32 (27.1%) were ACLF patients, 66 (55.9%) were CLD patients and 14 (11.9%) were post-LT patients. The most common Candida species isolated was C. tropicalis (22.9%), followed by C. glabrata (17.8%), C. albicans (16.9%), C. parapsilosis (12.7%), C. auris (8.5%), C. krusei (6.8%) and other Candida species (14.4%). The other Candida species isolated were C. haemulonii, C. kefyr, C. lusitaniae, C.pelliculosa, C. duobushaemulonii, C. lipolytica, and C. rugosa. The sensitivity to fluconazole (55.1%), voriconazole (86.4%), caspofungin (82.2%), micafungin (97.5%), flucytosine (80.5%), amphotericin B (86.4%). Mortality was 66%. Conclusion Our study shows that chronic liver disease, acute liver failure and liver transplantation are important risk factors for invasive candidiasis. There was a rise in the non-albicans Candida, especially C. tropicalis and C. glabrata. There is rising antifungal resistance to azoles and can lead to therapy failure. Hence antifungal sensitivity testing is essential in patients with these neglected risk factors to prevent mortality.
P004侵袭性念珠菌病被忽视的风险:肝病患者念珠菌的分布、种类分化及抗真菌药敏模式研究
摘要:海报会议1,2022年9月21日,下午12:30 - 1:30目的肝病(LD)患者更容易患念珠菌病,因为功能失调的库普弗细胞不能捕获循环酵母,从而导致真菌传播。念珠菌在终末期肝病患者中的发病率是其他LD患者的10倍。与腹部念珠菌病患者相比,肝移植受者(LTRs)伴有念珠菌病的ICU住院率和死亡率更高。虽然LD患者中大多数念珠菌感染是由白色念珠菌引起的,但非白色念珠菌分离株的患病率也在增加。本研究主要针对菌种分化和抗真菌敏感性进行研究。我们的目的是研究三级肝脏医院收治的不同LD患者血液中分离念珠菌的模式。目的:确定念珠菌在不同肝病状态患者中的分布。目的:测定肝病患者血液中分离的念珠菌种类。目的:探讨肝病患者血液中分离念珠菌的抗真菌药敏模式。目的:确定肝病患者血液中分离念珠菌的年变化趋势及其抗真菌药敏模式。材料与方法这是一项回顾性观察性研究,在新德里肝脏和胆道科学研究所(ILBS)微生物学系进行。本研究的伦理批准(IEC/2021/84/NA06)由机构伦理委员会/机构审查委员会提供。2017年1月至2020年12月期间入住ILBS的118例LD念珠菌患者被纳入研究。这些患者的临床细节从医院信息系统中收集。将LD患者分为急性肝衰竭(ALF)组、急性慢性肝衰竭(ACLF)组、慢性肝病(CLD)组和肝移植后(Post-LT)组。VITEK®2 (biomacrieux)鉴定假丝酵母菌种类,并通过肉汤微量稀释鉴定其抗真菌敏感性模式。结果118例LD患者的平均年龄为48.6±14.9岁[±标准差(SD)]。其中男性107例(90.7%),女性11例(9.3%)。118例LD患者中,ALF患者6例(5.1%),ACLF患者32例(27.1%),CLD患者66例(55.9%),lt后患者14例(11.9%)。检出的念珠菌种类以热带念珠菌(22.9%)最多,其次为光秃念珠菌(17.8%)、白色念珠菌(16.9%)、拟裂念珠菌(12.7%)、耳念珠菌(8.5%)、克氏念珠菌(6.8%)和其他念珠菌(14.4%)。分离到的其他念珠菌种有haemulonc、kefyr、lusitaniae、pelicullosa、duobushaemulonii、C. lipolytica和rugosa。对氟康唑(55.1%)、伏立康唑(86.4%)、卡泊芬金(82.2%)、米卡芬金(97.5%)、氟胞嘧啶(80.5%)、两性霉素B(86.4%)的敏感性。死亡率为66%。结论慢性肝病、急性肝功能衰竭和肝移植是侵袭性念珠菌病的重要危险因素。非白色念珠菌呈上升趋势,特别是热带念珠菌和光滑念珠菌。对唑类药物的抗真菌耐药性正在上升,并可能导致治疗失败。因此,抗真菌药敏试验对具有这些被忽视的危险因素的患者至关重要,以防止死亡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical mycology journal
Medical mycology journal Medicine-Infectious Diseases
CiteScore
1.80
自引率
10.00%
发文量
16
期刊介绍: The Medical Mycology Journal is published by and is the official organ of the Japanese Society for Medical Mycology. The Journal publishes original papers, reviews, and brief reports on topics related to medical and veterinary mycology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信